Stockreport

Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update

Barinthus Biotherapeutics plc - American Depositary Shares  (BRNS) 
PDF Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025Postponing further clinical development of VTP-300 in chronic hepatitis B (CHB) unt [Read more]